SAM
LXRX icon

Smartleaf Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Smartleaf Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-726
Closed -$1.26K – 2952
2024
Q2 		$1.26K Buy
+726
New +$1.3K ﹤0.01% 2364

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Smartleaf Asset Management's LXRX Position: Q3 2024 in Review

Smartleaf Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2024, closing a stake of 726 shares — an estimated $1.26K sold.

Smartleaf Asset Management first reported a position in LXRX in Q2 2024 and held it in 1 quarter. The position peaked at $1.26K in Q2 2024. 137 funds tracked by Wall St. Rank hold LXRX as of Q3 2024.

  • Smartleaf Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Smartleaf Asset Management sold 726 Lexicon Pharmaceuticals shares in Q3 2024, an estimated $1.26K.
  • Smartleaf Asset Management first reported a position in Lexicon Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Smartleaf Asset Management's Lexicon Pharmaceuticals position peaked at $1.26K in Q2 2024.
  • 137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2024.

Based on Smartleaf Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.